Unstable Angina Clinical Trial
Official title:
Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome: the Randomized, Multicenter, Double-blind ELECTRA RCT Study
The ELECTRA-SIRIO 2 study is a randomized, multicenter, double-blind, investigator-initiated clinical trial aimed to evaluate safety and efficacy of two ticagrelor-based de-escalation antiplatelet strategies in patients with acute coronary syndrome (ACS). During the hospitalization due to ACS, participants will be randomized in a 1:1:1 ratio into one of three arms: low-dose ticagrelor with aspirin (LDTA), low-dose ticagrelor with placebo (LDTP), and standard-dose ticagrelor with aspirin (SDTA), the latter being the control arm. Up to day 30, all enrolled patients will receive standard-dose ticagrelor (2x90mg) + aspirin (1x100mg). Starting from day 31 LDTA and LDTP patients will receive low-dose ticagrelor (2x60mg) + aspirin (1x100mg), SDTA - continuation of previous treatment. Starting from day 91 LDTP patients will receive low-dose ticagrelor (2x60mg) + placebo, SDTA and LDTA - continuation of previous treatment. The aim of the study is to evaluate the influence of ticagrelor maintenance dose reduction from 2x90mg to 2x60mg with or without continuation of aspirin versus dual antiplatelet therapy with standard dose ticagrelor in reducing clinically relevant bleeding and maintaining anti-ischemic efficacy in ACS patients.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05563701 -
Evaluation of the LVivo Image Quality Scoring (IQS)
|
||
Completed |
NCT04097912 -
Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
|
||
Not yet recruiting |
NCT03610529 -
CardioSenseSystem Compared Study Regarding Efficacy and Safety in the Monitoring of ECG
|
N/A | |
Withdrawn |
NCT03906812 -
A Randomized Trial of Telemetry Compared With Unmonitored Floor Admissions in ED Patients With Low-Risk Chest Pain
|
N/A | |
Completed |
NCT01826552 -
Comparison of the Angiographic Result of the Orsiro Hybrid Stent With Resolute Integrity Stent
|
Phase 4 | |
Completed |
NCT01709669 -
The Impact of Gratitude on Biology and Behavior in Persons With Heart Disease
|
N/A | |
Completed |
NCT01688648 -
Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft
|
N/A | |
Completed |
NCT01171404 -
Study Evaluating How Patients With Acute Coronary Syndrome Are Managed During 2 Years After Discharge
|
N/A | |
Completed |
NCT01167582 -
Myocardial Ischemia and Transfusion Pilot
|
Phase 3 | |
Completed |
NCT01020383 -
Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients
|
Phase 2 | |
Terminated |
NCT00355992 -
The Ischemia Modified Albumin In Diagnosing Ischemic New Events
|
N/A | |
Completed |
NCT00449826 -
Risk Stratification of Non ST Elevation ACS With Computed Tomographic Angiography (REACT)
|
N/A | |
Completed |
NCT00263263 -
RRISC Study: Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent.
|
Phase 2 | |
Active, not recruiting |
NCT04929496 -
Physiology as Guidance to Evaluate the Direct Impact of Coronary Lesion Treatment: The PREDICT Study
|
N/A | |
Completed |
NCT03103620 -
Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
|
||
Completed |
NCT04648306 -
Restore EF Observational Study
|
||
Not yet recruiting |
NCT03266289 -
Evaluation of Short Term Outcome of Different Bifurcation Stenting Techniques at Assuit University Cath. Lab
|
N/A | |
Not yet recruiting |
NCT04403048 -
Drug Coated Balloon for Side Branch Treatment vs. Conventional Approach in True Bifurcation Coronary Disease: PRO-DAVID
|
N/A | |
Recruiting |
NCT02748603 -
Appropriateness of Coronary Angioplasty in PAtients With isCHEmic Heart Disease
|
N/A | |
Completed |
NCT01774838 -
Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome
|
Phase 3 |